PHS
CYTK icon

PFM Health Sciences’s Cytokinetics CYTK Stock Holding History

PFM Health Sciences’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-268,600
Closed -$5.32M – 92
2021
Q2 		$5.32M Buy
+268,600
New +$6.31M 0.17% 77

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PFM Health Sciences's CYTK Position: Q4 2024 in Review

PFM Health Sciences sold out of Cytokinetics (CYTK) in Q4 2024, closing a stake of 1,757,192 shares — an estimated $92.8M sold.

PFM Health Sciences first reported a position in CYTK in Q4 2020 and held it in 16 quarters. The position peaked at $147M in Q4 2023. 346 funds tracked by Wall St. Rank hold CYTK as of Q4 2024.

  • PFM Health Sciences reported no remaining Cytokinetics position as of Q4 2024 after selling out during the quarter.
  • PFM Health Sciences sold 1,757,192 Cytokinetics shares in Q4 2024, an estimated $92.8M.
  • PFM Health Sciences first reported a position in Cytokinetics in Q4 2020 and held it in 16 quarters.
  • PFM Health Sciences's Cytokinetics position peaked at $147M in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2024.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.